The drug is intended to treat acute bacterial skin and skin structure infections caused by certain susceptible bacteria like Staphylococcus aureus, including methicillin-susceptible and methicillin-resistant strains, and Streptococcus pyogenes. The treatment is administered intravenously.
Dalvance is the first drug designated as a Qualified Infectious Disease Product to receive FDA approval. It was granted QIDP designation because it is an antibacterial or antifungal human drug intended to treat serious or life-threatening infections. As a QIDP, the drug was also given priority review.
More Articles on Quality:
Despite Guidelines, Antibiotics Prescribed at High Rate for Bronchitis
New Pathogen-Identification Method Leads to Cost Savings: Study
Kaiser South Sacramento Patients Potentially Exposed to Whooping Cough
